Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--<a href="" target="_blank">#DME</a>--Allegro Ophthalmics today announced positive topline results of its U.S. Phase 2 study of risuteganib for the treatment of intermediate dry AMD.

Full Story →